Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Theravance - THRX -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (21)	8/22/2006 5:44:08 PM
From: rkrw	Read Replies (1) \| Respond to of 74

Very close but not statistically superior in treating mrsa. Seems the telavancin group performed strongly, as expected, and the Vancomycin group performed quite a bit better than the phase IIs would have predicted. End result missed superiority by a sliver. MRSA results are strong though imo but would have been nice to cross the .05. Also no detail on the overall efficacies, maybe noninferior but slightly behind numerically? Should certainly be an approvable drug and what's impressive to me is this is a thrx invented drug, not another big pharma outcast antibiotic invented 20 years ago like cubicin and some others inlicensed elsewhere.